We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
A review of the evidence on the use and harms of 2-benzyl benzimidazole (nitazene) and piperidine benzimidazolone (brorphine-like) opioids.
Professor Owen Bowden-Jones, Chair, Advisory Council on the Misuse of…
1. Introduction 1.1. New psychoactive substances (NPS) have presented a…
Rt. Hon. Priti Patel MP Home Secretary 2 Marsham Street London SW1P 4DF…
On 18 July 2022 the Advisory Council on the Misuse of Drugs (ACMD)…
06 October 2023 Addendum to ACMD’s report on the use and harms of 2-benzyl…
Rt Hon Chris Philp MP Minister of State for Crime, Policing and Fire | 2…
15 December 2023 Third addendum to ACMD report on the use and harms of…
Rt Hon Chris Philp MP Minister of State for Crime, Policing and Fire 2…
5 April 2024 On 12 December 2023, the ACMD published a third addendum to…
A review of the evidence on the use, harms and prevalence of recently encountered uncontrolled novel benzodiazepines and related compounds (2024 update).
ACMD Chair: Prof Owen Bowden-Jones NPS Committee Secretary: Yetunde…
This report has considered the harms and control of 2-methyl-AP-237 and other closely related acyl piperazine opioids.
1. Introduction 1.1. New synthetic opioids (NSO) have been identified as a…
ACMD Chair: Prof Owen Bowden-Jones Acyl Piperazine Opioids Working Group…
Review of the evidence on the use and harms of xylazine, medetomidine and detomidine.
Recommendations from the ACMD to reduce barriers to research for schedule 1 controlled drugs.
Report from the Advisory Council on the Misuse of Drugs (ACMD) on consumer cannabidiol (CBD) products.
The Advisory Council on the Misuse of Drugs has undertaken a review of the availability and implementation of naloxone in the UK.
The Advisory Council on the Misuse of Drugs (ACMD) has provided advice on the scheduling of nitrous oxide.
This report provides an updated assessment of the health and social harms of nitrous oxide.
The Advisory Council on the Misuse of Drugs has undertaken a review of the evidence on the use and harms of Cumyl-PeGaClone.
The Advisory Council on the Misuse of Drugs has undertaken a review of the evidence on the use and harms of diphenidine and other related substances.
Recommendations to reduce barriers to research, using compounds described by the third generation synthetic cannabinoid receptor agonists generic definition.
This report provides an updated harms assessment to the ACMD's previous reports on synthetic cannabinoid receptor agonists.
Advice on preventing drug misuse among vulnerable groups of people, with a focus on understanding factors that contribute to vulnerability.
An assessment of the impact of rescheduling CBPMs to Schedule 2 under the Misuse of Drugs Regulations 2001 (MDR) and recommendations to mitigate the issues identified.
This report provides an updated harms assessment of gamma-hydroxybutyric acid (GHB) and related substances.
This report examines the evidence of prevalence and harms in the UK of several novel benzodiazepines and provides advice to the government.
The Advisory Council on the Misuse of Drugs (ACMD) summarise their contribution to the impact review of the Psychoactive Substances Act 2016
ACMD report providing advice to the government on the factors that make the homeless population vulnerable to substance misuse harms and how these can reduced.
Report from the ACMD providing advice to the government on the changing age profile of people accessing drug treatment and the challenges faced by this cohort in the UK.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.